Fmr LLC Continues to Hold Stake in Zosano Pharma Corporation (NASDAQ:ZSAN)

FMR LLC held its position in Zosano Pharma Corporation (NASDAQ:ZSAN) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,776,019 shares of the biotechnology company’s stock at the end of the first quarter. FMR LLC owned 9.13% of Zosano Pharma Corporation worth $3,374,000 at the end of the most recent reporting period.

Separately, Granite Point Capital Management L.P. purchased a new position in Zosano Pharma Corporation during the first quarter worth $285,000. Institutional investors and hedge funds own 23.91% of the company’s stock.

Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) opened at 0.8185 on Friday. Zosano Pharma Corporation has a 12-month low of $0.45 and a 12-month high of $3.54. The company has a 50-day moving average of $1.19 and a 200-day moving average of $1.57. The stock’s market capitalization is $32.11 million.

Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. During the same period last year, the firm earned ($0.54) EPS. Equities analysts expect that Zosano Pharma Corporation will post ($0.79) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/zosano-pharma-corporation-nasdaqzsan-position-held-by-fmr-llc-updated-updated.html.

Separately, ValuEngine raised shares of Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 6th.

In related news, CEO John Peter Walker purchased 73,716 shares of Zosano Pharma Corporation stock in a transaction dated Thursday, May 25th. The stock was acquired at an average cost of $1.36 per share, with a total value of $100,253.76. Following the completion of the transaction, the chief executive officer now directly owns 169,344 shares of the company’s stock, valued at $230,307.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Georgia Erbez purchased 68,000 shares of Zosano Pharma Corporation stock in a transaction dated Thursday, May 25th. The stock was bought at an average cost of $1.32 per share, with a total value of $89,760.00. Following the completion of the transaction, the chief financial officer now directly owns 115,750 shares of the company’s stock, valued at $152,790. The disclosure for this purchase can be found here. 2.95% of the stock is owned by corporate insiders.

About Zosano Pharma Corporation

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Institutional Ownership by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)

What are top analysts saying about Zosano Pharma Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zosano Pharma Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit